Drug intelligence / Profile preview

semax + selank

Development stage
Preclinical
Lead developer
Peptogen
Modality
Peptides
Administration
Intranasal, Subcutaneous
01

Overview

Semax + Selank is a combination of two synthetic heptapeptides developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analog of the adrenocorticotropic hormone (ACTH) fragment ACTH(4-7) with a Pro-Gly-Pro C-terminal tail added for enzymatic stability. It acts primarily as a cognitive enhancer and neuroprotectant by upregulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) via the CREB pathway, and modulating dopaminergic and serotonergic systems. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the endogenous immunomodulatory peptide tuftsin, also stabilized with a Pro-Gly-Pro tail. It acts primarily as an anxiolytic and immunomodulator, modulating GABAergic neurotransmission, inhibiting enkephalin-degrading enzymes, and regulating serotonin metabolism. The combination is popular in the nootropic and wellness communities as a 'stack' or co-formulated nasal spray to simultaneously enhance focus, memory, and mental clarity (via Semax) while promoting calm, stress resilience, and emotional stability (via Selank) without causing sedation or dependence.

Other names
semax + selank blendsemax + selank nasal spraysemax and selanksemax and selank blendsemax and selank nasal spraysemax/selanksemax/selank blend
02

Targets

ACE (Angiotensin Converting Enzyme)GABRR (GABA-A receptor subunit rho)MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)NGF (Nerve growth factor)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on semax + selank.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on semax + selank.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call